Tags

Type your tag names separated by a space and hit enter

Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest.
Contraception. 1997 Sep; 56(3):185-91.C

Abstract

Twenty-two healthy female volunteers with normal ovulatory cycles, aged between 20 and 34 years (27.3 +/- 4.1), were included in a single-center, noncomparative study to investigate the modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest. At baseline, during three treatment cycles and post-treatment, serum levels of luteinizing hormone, follicle-stimulating hormone, 17 beta-estradiol, and progesterone were assayed and ultrasonography was used to measure follicular size and the thickness of the endometrium. The primary efficacy variable was inhibition of ovulation as measured by ovarian activity grading. All volunteers ovulated during the pretreatment cycle. During treatment, none of the subjects had ovulatory cycles, although there was still some ovarian activity in several subjects. During the first treatment cycle, only 4% (1 subject) of cycles showed active follicle-like structures. The frequency of follicle-like structures increased to 33% and 35% during treatment cycles 2 and 3. The frequency of presumptive luteinized unruptured follicle-like structures was 5% (1 subject) and 15% (3 subjects) in treatment cycles 2 and 3. The serum hormone concentrations were effectively suppressed in comparison to baseline. The ovarian activity returned to baseline during the post-treatment period. One subject was excluded from further study because of a medical problem believed unrelated to use of the oral contraceptive. No serious adverse events were recorded during the course of the study. The results of the present investigation indicate that the modulatory effects on ovarian function of the monophasic oral-contraceptive containing 30 micrograms ethinyl estradiol combined with 2.00 mg dienogest lead to adequate suppression of ovarian activity and effective inhibition of ovulation.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, University of Vienna, Austria.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

9347211

Citation

Spona, J, et al. "Modulation of Ovarian Function By an Oral Contraceptive Containing 30 Micrograms Ethinyl Estradiol in Combination With 2.00 Mg Dienogest." Contraception, vol. 56, no. 3, 1997, pp. 185-91.
Spona J, Feichtinger W, Kindermann C, et al. Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest. Contraception. 1997;56(3):185-91.
Spona, J., Feichtinger, W., Kindermann, C., Moore, C., Mellinger, U., Walter, F., & Gräser, T. (1997). Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest. Contraception, 56(3), 185-91.
Spona J, et al. Modulation of Ovarian Function By an Oral Contraceptive Containing 30 Micrograms Ethinyl Estradiol in Combination With 2.00 Mg Dienogest. Contraception. 1997;56(3):185-91. PubMed PMID: 9347211.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest. AU - Spona,J, AU - Feichtinger,W, AU - Kindermann,C, AU - Moore,C, AU - Mellinger,U, AU - Walter,F, AU - Gräser,T, PY - 1997/11/5/pubmed PY - 1997/11/5/medline PY - 1997/11/5/entrez KW - Austria KW - Biology KW - Clinical Research KW - Clinical Trials KW - Contraception KW - Contraceptive Agents, Estrogen--administraction and dosage KW - Contraceptive Agents, Female--administraction and dosage KW - Contraceptive Agents, Progestin--administraction and dosage KW - Contraceptive Agents--administraction and dosage KW - Contraceptive Methods--administraction and dosage KW - Contraceptive Mode Of Action KW - Developed Countries KW - Endocrine System KW - Endometrial Effects KW - Endometrium KW - Ethinyl Estradiol--administraction and dosage KW - Europe KW - Family Planning KW - Follicle Stimulating Hormone--analysis KW - Genitalia KW - Genitalia, Female KW - Gonadotropins KW - Gonadotropins, Pituitary KW - Hormones KW - Luteinizing Hormone--analysis KW - Oral Contraceptives, Combined--administraction and dosage KW - Oral Contraceptives--administraction and dosage KW - Ovarian Effects KW - Ovary KW - Ovulation Suppression KW - Physiology KW - Research Methodology KW - Research Report KW - Urogenital System KW - Uterus KW - Western Europe SP - 185 EP - 91 JF - Contraception JO - Contraception VL - 56 IS - 3 N2 - Twenty-two healthy female volunteers with normal ovulatory cycles, aged between 20 and 34 years (27.3 +/- 4.1), were included in a single-center, noncomparative study to investigate the modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest. At baseline, during three treatment cycles and post-treatment, serum levels of luteinizing hormone, follicle-stimulating hormone, 17 beta-estradiol, and progesterone were assayed and ultrasonography was used to measure follicular size and the thickness of the endometrium. The primary efficacy variable was inhibition of ovulation as measured by ovarian activity grading. All volunteers ovulated during the pretreatment cycle. During treatment, none of the subjects had ovulatory cycles, although there was still some ovarian activity in several subjects. During the first treatment cycle, only 4% (1 subject) of cycles showed active follicle-like structures. The frequency of follicle-like structures increased to 33% and 35% during treatment cycles 2 and 3. The frequency of presumptive luteinized unruptured follicle-like structures was 5% (1 subject) and 15% (3 subjects) in treatment cycles 2 and 3. The serum hormone concentrations were effectively suppressed in comparison to baseline. The ovarian activity returned to baseline during the post-treatment period. One subject was excluded from further study because of a medical problem believed unrelated to use of the oral contraceptive. No serious adverse events were recorded during the course of the study. The results of the present investigation indicate that the modulatory effects on ovarian function of the monophasic oral-contraceptive containing 30 micrograms ethinyl estradiol combined with 2.00 mg dienogest lead to adequate suppression of ovarian activity and effective inhibition of ovulation. SN - 0010-7824 UR - https://www.unboundmedicine.com/medline/citation/9347211/Modulation_of_ovarian_function_by_an_oral_contraceptive_containing_30_micrograms_ethinyl_estradiol_in_combination_with_2_00_mg_dienogest_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0010782497001236 DB - PRIME DP - Unbound Medicine ER -